Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial): Study Protocol for a Multi-center, Double-blinded, Placebo-controlled, Randomized Clinical Trial
Who is this study for? Patients with Acute Pancreatitis, Complication
What treatments are being studied? Indomethacin SR
Status: Recruiting
Location: See all (17) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Acute pancreatitis (AP) is an inflammatory condition of the pancreas following the activated pancreatic enzymes induced by varied causes, with or without other organ(s) dysfunction. The production and release of inflammatory factors is generally considered as the key factor of pathogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly applied agents for inflammatory diseases. A series studies have proved that indomethacin can reduce the risk of post-endoscopic retrograde cholangiopancreatography (ERCP), but high-quality evidence is still lacking in the field of effectiveness of NSAIDs to treat, rather than prevent, other types of AP. Majority of animal experiments showed that NSAIDs had protective effects for organ functions, but the results of several preliminary clinical studies were inconsistent. Randomized controlled trials are eagerly awaited to elucidate its effects on AP.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• All patients ages 18-80 years with a diagnosis of AP based on at least 2 of the following criteria:
• Abdominal pain characteristic of AP
• Serum amylase and/or lipase ≥ 3 times the upper limit of normal
• Characteristic findings of AP on abdominal CT scan will be screened for study enrollment.
Locations
Other Locations
China
Baoding Seventh Hospital
RECRUITING
Baoding
Liangxiang Hospital
RECRUITING
Beijing
Peking Union Medical College Hospital
RECRUITING
Beijing
Peking University Sixth Hospital
RECRUITING
Beijing
West China Longquan Hospital Sichuan University
RECRUITING
Chengdu
Dengzhou People's Hospital
RECRUITING
Dengzhou
Guiyang Second People's Hospital
RECRUITING
Guiyang
Fourth Affiliated Hospital of Harbin Medical University
RECRUITING
Harbin
The Second People's Hospital of Huai'an
RECRUITING
Huaian
Jinhua Municipal Central Hospital
RECRUITING
Jinhua
Lishui Municipal Central Hospital
RECRUITING
Lishui
Nantong First People's Hospital
RECRUITING
Nantong
Second People Hospital of Nanyang
RECRUITING
Nanyang
Suqian People's Hospital
RECRUITING
Suqian
The First Affiliated Hospital of Xinjiang Medical University
RECRUITING
Ürümqi
Wuxi Third People's Hospital
RECRUITING
Wuxi
Qinghai University Affiliated Hospital
RECRUITING
Xining
Contact Information
Primary
Dong Wu, M.D.
dongwu@pumc.edu.cn
8618612671010
Time Frame
Start Date:2024-12-01
Estimated Completion Date:2028-12-01
Participants
Target number of participants:1504
Treatments
Experimental: Indomethacin group
Indomethacin SR 50mg q12h from day1 to day 7 plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
Sham_comparator: Standard group
Similar shape and size suppositories without indomethacin (Placebos) given q12h from admission day 1 to day 7, plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.